In recent years, some molecular targeted drugs such as trastuzumab and ramucirumab (an antibody against vascular endothelial growth factor 2 receptor) have also been approved for the treatment of advanced gastric cancer, but the median survival rate of patients with gastric cancer (less than 1 year) is still very low [4]. The gene discussed is KDR; the disease is gastric cancer.